Andre Konski, MD, MBA, MA, FACR Professor & Chair Department of Radiation Oncology Wayne State University School of Medicine Barbara Ann Karmanos
|
|
|
- Patrick Jennings
- 8 years ago
- Views:
Transcription
1 Andre Konski, MD, MBA, MA, FACR Professor & Chair Department of Radiation Oncology Wayne State University School of Medicine Barbara Ann Karmanos Cancer Center
2 Financial None The views that I will be going to express in this talk are not the views of ASTRO
3 ETC started by Dr. Ted Lawrence Original Co-Chairs Drs. Paul Wallner and Andre Konski Started Oct 2005 Proton Therapy report initiated May 2007 All sections completed 1/09 and sent to Evaluation Subcommittee Chairs Report to be also sent to ASTRO Proton Therapy Task Force
4 July Final report ready for final review Sent to select group of reviewers from ESTRO Philip Lambin, Michael Bauman, Dag Rune Olsen, Jens Overgaard and Michael Joiner (USA Biology review) Expert review completed 9/2009 Final report 11/09 Sent to Proton Task Force 12/09 Proton Task Force completed 3/10
5 ASTRO legal review completed 4/10 Public comments on the report received 6/10 Original report was 100+ pages with over 200 references Proton report submitted to Cancer-Rejected Proton report submitted to JNCI-Rejected Proton report submitted to JCO-Rejected Proton report submitted to PRO-Rejected
6 Submitted to Radiotherapy & Oncology Oct/11 Rejected, Resubmitted and Received in revised form 1/12 Accepted 2/12 Available on line 3/12 For all of you Oliver Stone fans Why is an official work product of ASTRO published in the official journal of ESTRO?
7 Full report available on line at: cal_practice/protonbeamreport.pdf
8
9 CNS Lung Ocular Melanoma GI Prostate Head and Neck Pediatrics
10 Clinical data from PBT or mixed photon/pbt for base of skull tumors appear superior to previously published series of conformal photon radiotherapy However, stereotactic photon radiosurgery may provide a significant dosimetric and clinical advantage to standard conformal (3D or IMRT) radiotherapy techniques. Overall, more clinical data (published clinical trials) are needed to fully establish the role of PBT in CNS tumors.
11 PBT has been used in the treatment of stage I NSCLC although no clear clinical benefit over photon therapy has currently been shown. Data regarding the use of PBT in other clinical scenarios remain limited and do not provide sufficient evidence to recommend PBT for lung cancer outside of clinical trials. In addition, unlike in some other disease sites, the issue of organ motion in lung cancer is critical and adds an additional challenge to the use of PBT.
12 PBT is mostly untested in GI malignancies, and the number of patients with GI malignancies who are eligible for PBT will be very small until indications for its use become clearer. In rectal and gastric cancers there appears to be little role for PBT.
13 In esophageal and pancreatic cancers there may be a rationale for PBT, as these are two sites often with localized unresectable disease near critical organs at risk, but almost no clinical data exist. In hepatocellular cancer there appears to be the most data and perhaps promise for PBT as an alternative to photon base approaches, but more rigorous study and prospective clinical trials are necessary to definethe differences in toxicity and efficacy between protons and photons.
14 PBT has been shown to be effective in the treatment of large ocular melanomas not approachable via brachytherapy. In the group of intermediate tumors that has been well studied by the COMS (Collaborative Ocular Melanoma Study) group, there is evidence for efficacy of both PBT and brachytherapy. Further comparative studies will help select patients for the appropriate therapy.
15 Most patients treated with protons No clear evidence from both in terms of outcome and toxicity Head to head clinical trials needed Actually going to happen at Penn and MGH Based on current data, proton therapy is an option for prostate cancer, but no clear benefit over the existing therapy of IMRT photons has been demonstrated.
16 Until IMPBT is more fully developed and tested, it will be difficult to establish whether PBT may be equivalent to photon IMRT in treating full head and neck plans. Further clinical data through prospective clinical trials are needed regarding cases in which the target is the primary volume located near critical structures. There are insufficient data to recommend PBT for routine head and neck radiation therapy outside of clinical trials.
17 PBT has perhaps its most developed place in pediatric brain tumors. Although the clinical evidence is lacking, the rationale for using PBT in posterior fossa tumors, optic pathway tumors, and brainstem lesions is compelling. Future clinical studies reporting on the outcome of patients treated with protons will decide how widespread protons become for pediatric CNS tumors.
18 There does not appear to be sufficient evidence at this time to recommend treatment with protons for non-cns pediatric malignancies.
19 Johnstone et al JACR 9(8):
20 Blue Shield Foundation of California spearheads the California Technology Assessment Forum (CTAF), managing technology assessment reviews and organizing all CTAF meetings and events. Neither CTAF nor BSFC are revenue-generating organizations, consultant organizations, endorsers of specific technologies, advocacy organizations, or organizations that determine health plan benefit coverage. Recently released an assessment of Proton Beam Therapy for Prostate Cancer
21 TA Criterion 1: The technology must have final approval from the appropriate government regulatory bodies. Met criteria TA Criterion 2: The scientific evidence must permit conclusions concerning the effectiveness of the technology regarding health outcomes. Met criteria
22 TA Criterion 3: The technology must improve the net health outcomes. Met Criteria TA Criterion 4: The technology must be as beneficial as any established alternatives. Criteria not met TA Criterion 5: The improvement must be attainable outside the investigational settings. Criteria not met
23 It is recommended that proton beam therapy for localized prostate cancer does not meet CTAF criteria 4 or 5 for safety, efficacy and improvement in health outcomes.
24 Disease Site CNS Lung Ocular Melanoma GI Prostate Head and Neck Pediatrics Conclusion More clinical data needed More clinical data needed; Organ motion needs to be a addressed Role for PBT Role depending upon disease sites Most data for this site and appears to be viable option Difficult to establish role until IMPT is established No clear evidence outside of CNS
25 ASTRO ETC report shows there are a few sites potentially to benefit from the use of Proton Beam Therapy CTAF report not favorable Further studies as outlined needed to define role of Proton Beam Therapy
Current Status and Future Direction of Proton Beam Therapy
Current Status and Future Direction of Proton Beam Therapy National Cancer Center Hospital East Division of Radiation Oncology and Particle Therapy Tetsuo Akimoto Comparison of status of particle therapy
Medical Marijuana Use in Patients with History of SCCHN Treated with Radiotherapy
HEALTH SERVICES RESEARCH Assessment the Impact of Real-time Tumor Tracking & Reduced Planning Target Volume Margins on Quality-of-Life in Prostate Cancer Patients Treatment with Intensity Modulated Radiotherapy
Clinical Education A comprehensive and specific training program. carry out effective treatments from day one
Proton Therapy Clinical Education A comprehensive and specific training program carry out effective treatments from day one Forewarned is forearmed Although over 100,000 patients have been treated in proton
Key Staff Members EXECUTIVE TEAM Nancy Price Mendenhall, MD Medical Director Stuart Klein, MHA Executive Director Zuofeng Li, DSc Physics Director
Key Staff Members EXECUTIVE TEAM Nancy Price Mendenhall, MD Medical Director A University of Florida College of Medicine faculty member since 1985, Dr. Mendenhall served as the chair of the Department
Protons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D.
Protons vs. CyberKnife UC SF Protons vs. CyberKnife UC SF Alexander R. Gottschalk, M.D., Ph.D. Associate Professor and Director of the CyberKnife Radiosurgery Program Department of Radiation Oncology University
PROTON THERAPY. Proton Therapy World Market Report Edition 2015 WORLD MARKET REPORT EDITION 2015. MEDraysintell. 2015 www.medraysintell.
Proton Therapy World Market Report Edition 2015 PROTON THERAPY WORLD MARKET REPORT EDITION 2015 A report written by Paul-Emmanuel Goethals & Richard Zimmermann Page 1/7 www.medraysintell.com Proton Therapy
The Science behind Proton Beam Therapy
The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related
Proton Therapy: Is This Technology a Correct Fit for Your Radiation Oncology Service?
Society for Radiation Oncology Administrators Annual Meeting Proton Therapy: Is This Technology a Correct Fit for Your Radiation Oncology Service? Date Pasadena, California October 30, 2007 903 Airport
Proton Therapy Center Czech
Proton Therapy Center Czech The main goal of radiotherapy is to irreversibly damage tumor cells, whereas the cells of healthy tissue are damaged only reversibly or not at all. Proton therapy currently
Implementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
Skandionkliniken. Current Clinical Evidence for Proton Therapy. Valtakunnalliset onkologiapäivät 2013 Turussa.
Skandionkliniken Current Clinical Evidence for Proton Therapy Valtakunnalliset onkologiapäivät 2013 Turussa. Thomas Björk-Eriksson, senior consultant and associate professor Skandionkliniken and Sahlgrenska
Executive summary. What is proton radiotherapy?
Executive summary Health Council of the Netherlands. Proton radiotherapy. Horizon scanning report. The Hague: Health Council of the Netherlands, 2009; publication no. 2009/17 What is proton radiotherapy?
Radiation Therapy in Prostate Cancer Current Status and New Advances
Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Presentation Welcome Overview of UCSD, Moores
Our Facility. Advanced clinical center with the newest and highly exact technology for treatment of patients with cancer pencil beam
PTC Czech The main goal of radiotherapy is to irreversibly damage tumor cells, whereas the cells of healthy tissue are damaged only reversibly or not at all. Proton therapy currently comes closest to this
Accreditation a tool to help reduce medical errors. Professor Arthur T Porter PC MD FACR FRCPC FACRO
Accreditation a tool to help reduce medical errors Professor Arthur T Porter PC MD FACR FRCPC FACRO Errors in Radiotherapy Radiation therapy is a highly regulated medical practice with historically low
Radiation Therapy in Prostate Cancer Current Status and New Advances
Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Radiation Therapy Wilhelm Roentgen (1845-1923)
1. Provide clinical training in radiation oncology physics within a structured clinical environment.
Medical Physics Residency Program Overview Our Physics Residency Training is a 2 year program typically beginning July 1 each year. The first year resident will work closely with medical physicists responsible
There must be an appropriate administrative structure for each residency program.
Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation
Proton Therapy: Science Fiction or Science Fact
Proton Therapy: Science Fiction or Science Fact John Han-Chih Chang, MD Director of Clinical Research CDH Proton Center Primary Investigator - Radiation Therapy Oncology Group Primary Investigator - Children
Comments. This is factually incorrect. I suggest replacement with the following:
Comments LCD Title Proton Beam Therapy Contractor's Determination Number RAD-040 1. Comment Three comments are related to the first paragraph in the policy. a. In the section Indications and Limitations
SAFE HARBOR STATEMENT
JUNE 14, 2016 SAFE HARBOR STATEMENT This presentation may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American
Proton Therapy for Prostate Cancer: Your Questions, Our Answers.
Proton Therapy for Prostate Cancer: Your Questions, Our Answers. When you re looking for the right treatment for your prostate cancer, nothing s more important than accurate information. Read on, and learn
Proton Therapy: Cutting Edge Treatment for Cancerous Tumors. By: Cherilyn G. Murer, JD, CRA
Proton Therapy: Cutting Edge Treatment for Cancerous Tumors By: Cherilyn G. Murer, JD, CRA Introduction Put simply, proton therapy is a new cutting edge cancer treatment that promises better outcomes for
IEHP UM Subcommittee Approved Authorization Guidelines Proton Beam Radiation therapy for Prostate Cancer
Proton Beam Radiation therapy for Prostate Cancer Policy: The use of Proton Beam Therapy (PBT) in Prostate cancer has not been established as more effective than other forms of External Beam Radiation
In 1946 Harvard physicist Robert Wilson (1914-2000) suggested:
In 1946 Harvard physicist Robert Wilson (1914-2000) suggested: Protons can be used clinically Accelerators are available Maximum radiation dose can be placed into the tumor Proton therapy provides sparing
THE POWER AND PRECISION OF PROTON BEAM THERAPY IS WITHIN REACH
THE POWER AND PRECISION OF PROTON BEAM THERAPY IS WITHIN REACH PROTON THERAPY OVERVIEW The American Cancer Society estimates 1.6 million new cancer cases in the United States this year. Approximately two
Subject: Proton Beam Therapy for Prostate Cancer
Subject: Proton Beam Therapy for Prostate Cancer Guidance Number: MCG-153 Revision Date(s): Original Effective Date: 10/30/13 Medical Coverage Guidance Approval Date: 10/30/13 PREFACE This Medical Guidance
Radiation Treatment Capital Investment Strategy
Radiation Treatment Capital Investment Strategy April 2012 1.0 EXECUTIVE SUMMARY... 1 2.0 INTRODUCTION AND BACKGROUND... 5 3.0 RADIATION TREATMENT CAPACITY... 8 3.1 Planning Parameters... 9 3.2 Regional
The 2 nd Taiwan-Japan Conference on the High Precision Radiation Therapy
第 2 屆 台 灣 - 日 本 高 精 度 放 射 線 治 療 研 討 會 The 2 nd Taiwan-Japan Conference on the High Precision Radiation Therapy 議 程 Program The 2 nd Taiwan-Japan Conference on the High Precision Radiation Therapy 7 Information
INTERPRETING CLINICAL DATA: Highlights From ASCO 2016
INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 SATURDAY, JUNE 25, 2016 Detroit Marriott - Troy, MI AGENDA Time Topic Speaker 7:30 am Registration and Continental Breakfast 8:00 am Opening Remarks/Welcome
Particle Therapy for Lung Cancer. Bradford Hoppe MD, MPH Assistant Professor University of Florida bhoppe@floridaproton.org
Particle Therapy for Lung Cancer Bradford Hoppe MD, MPH Assistant Professor University of Florida bhoppe@floridaproton.org Content Rationale for Particle Therapy in Lung Cancer Proof of Principle Treatment
Proton Therapy for Cancer: A New Technology Brief
September 8, 2009 Volume 6 / Number 17 A Closer Look This is the second article in a series of stories related to cancer technology. Look for the symbol on the left in an upcoming issue for the next article
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results Alan Katz MD JD Flushing, NY USA Prostate Ablative Therapy Over the last 10 years our therapy has improved bned rates for LDR/HDR
Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment
Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy) for Paediatric Cancer Treatment Reference: NHS England xxx/x/x 1 Clinical Commissioning Policy: Proton Beam Radiotherapy (High Energy)
Comparative Effectiveness of Proton Irradiation Treatment
Department of Veterans Affairs Health Services Research & Development Service Comparative Effectiveness of Proton Irradiation Treatment January 2015 Prepared for: Department of Veterans Affairs Veterans
Corporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Head and Neck File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_head_and_neck
Effective for dates of service on or after May 1, 2015, refer to: Blue Cross and Blue Shield of Alabama Radiation Therapy Management RTM Policies
Effective for dates of service on or after May 1, 2015, refer to: Blue Cross and Blue Shield of Alabama Radiation Therapy Management RTM Policies Name of Policy: Charged-Particle (Proton or Helium Ion)
FAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
RADIATION THERAPY FOR BRAIN METASTASES. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY
RADIATION THERAPY FOR BRAIN METASTASES Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT BRAIN METASTASIS Brain metastases are clusters
Radiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
PROTON BEAM RADIATION THERAPY
PROTON BEAM RADIATION THERAPY MEDICAL POLICY Policy Number: 2015T0132S Effective Date: October 1, 2015 Table of Contents BENEFIT CONSIDERATIONS COVERAGE RATIONALE APPLICABLE CODES.. DESCRIPTION OF SERVICES...
IBA Proton Therapy. Biomed days 2015. Vincent Bossier. System Architect Vincent.bossier@iba-group.com. Protect, Enhance and Save Lives
Vincent Bossier System Architect Vincent.bossier@iba-group.com IBA Proton Therapy Biomed days 2015 Protect, Enhance and Save Lives 1 Agenda AN INTRODUCTION TO IBA WHY PROTON THERAPY CLINICAL WORKFLOW TREATMENT
Proton beam. Medical Technical Complex Joint Institute for Nuclear Research, Dubna, Russia
Proton beam Medical Technical Complex Joint Institute for Nuclear Research, Dubna, Russia Egyptian Candidates Proton therapy It can do more!!! Effectiveness of the proton therapy in targeting and curing
Proton Beam Radiotherapy Data Points # 10
Proton beam radiotherapy in the U.S. Medicare population: growth in use between 2006 and 2009 Proton Beam Radiotherapy Data Points # 10 Proton beam radiotherapy is a form of external beam radiation that
HADRON THERAPY FOR CANCER TREATMENT
HADRON THERAPY FOR CANCER TREATMENT Seminar presented by Arlene Lennox at Fermilab on Nov 21, 2003 CANCER STAGES LOCAL TUMOR REGIONAL METASTASIS SYSTEMIC DISEASE CANCER TREATMENT SURGERY RADIATION THERAPY
Proton Therapy. What is proton therapy and how is it used?
Scan for mobile link. Proton Therapy Proton therapy delivers radiation to tumor tissue in a much more confined way than conventional photon therapy thus allowing the radiation oncologist to use a greater
at a critical moment Physician Suggestion Line...
Radiation Oncology Exceptional care at a critical moment When your patients require radiation therapy, they deserve the very best care available to them. The Department of Radiation Oncology provides exceptional
BRACHYTHERAPY FOR TREATMENT OF BREAST CANCER
BRACHYTHERAPY FOR TREATMENT OF BREAST CANCER Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
Radiotherapy in Hungary: present status and future needs. Tibor Major, PhD National Institute of Oncology Radiotherapy Department Budapest, Hungary
Radiotherapy in Hungary: present status and future needs Tibor Major, PhD National Institute of Oncology Radiotherapy Department Budapest, Hungary Academia Europaea Section Workshops, Bergen, 10 September,
Current and Future Trends in Proton Treatment of Prostate Cancer
Current and Future Trends in Proton Treatment of Prostate Cancer Reinhard W. Schulte Assistant Professor Department of Radiation Medicine Loma Linda University Medical Center Loma Linda, CA, USA Outline
Charged-Particle (Proton or Helium Ion) Radiotherapy
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Charged-Particle (Proton or Helium Ion) Radiotherapy Number 8.01.534
Radiation Therapy for Cancer Treatment
Radiation Therapy for Cancer Treatment Guest Expert: Kenneth, MD Associate Professor of Therapeutic Radiology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and
Gamma Knife and Axesse Radiosurgery
Gamma Knife and Axesse Radiosurgery John C Flickinger MD Departments of Radiation Oncology & Neurological Surgery University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania Origin of Radiosurgery
How To Treat Cancer With A Proton Beam
Original Issue Date (Created): July 10, 2002 Most Recent Review Date (Revised): September 30, 2014 Effective Date: January 1, 2015- RETIRED* POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
PROTON THERAPY FREQUENTLY ASKED QUESTIONS
PROTON THERAPY FREQUENTLY ASKED QUESTIONS Table of contents 1. What is cancer?... 2 2. How is cancer treated?... 3 3. What is proton therapy?... 4 4. What are the clinical benefits of proton therapy?...
Potential Benefits of Proton Therapy in Clinic
Potential Benefits of Proton Therapy in Clinic Simone Pieplenbosch Proton therapy offers great potential in cancer treatment compared with the conventional photon therapy. The advantages of the unique
Training Requirements for the Specialty of Radiation Oncology
Association internationale sans but lucratif AVENUE DE LA COURONNE, 20 BE- 1050 BRUSSELS www.uems.net International non-profit organisation T +32 2 649 51 64 F +32 2 640 37 30 info@uems.net Training Requirements
PROTON BEAM THERAPY FOR PROSTATE CANCER. A Technology Assessment
PROTON BEAM THERAPY FOR PROSTATE CANCER A Technology Assessment INTRODUCTION The California Technology Assessment Forum is requested to review the scientific evidence for the use of proton therapy for
MEDICARE. Higher Use of Costly Prostate Cancer Treatment by Providers Who Self- Refer Warrants Scrutiny. Report to Congressional Requesters
United States Government Accountability Office Report to Congressional Requesters July 2013 MEDICARE Higher Use of Costly Prostate Cancer Treatment by Providers Who Self- Refer Warrants Scrutiny GAO-13-525
2015 ASTRO INVESTOR MEETING. October 20, 2015
2015 ASTRO INVESTOR MEETING October 20, 2015 Agenda 7:30AM Welcome Dow Wilson Our Cancer Care Vision: The Next Big Advances Kolleen Kennedy Particle Therapy: Building Momentum Dow Wilson Q & A 9:00AM Booth
Conventional treatment modalities do not provide adequate local tumor control,
Medical Policy Manual Topic: Charged-Particle (Proton or Helium Ion) Radiation Therapy Date of Origin: April 1998 Section: Medicine Last Reviewed Date: June 2015 Policy No: 49 Effective Date: August 1,
The Center for Cancer Care. Comprehensive and compassionate care
The Center for Cancer Care Comprehensive and compassionate care Welcome to the Center for Cancer Care The Center for Cancer Care at Exeter Hospital provides comprehensive, compassionate care for a wide
National Clinical Trials Network Groups Update Fall 2014
National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update
APA format (title page missing) Proton Therapy 3. A paper. A New Cancer Treatment: Proton Therapy. A Review of the Literature
APA format (title page missing) Proton Therapy 3 A paper A New Cancer Treatment: Proton Therapy A Review of the Literature Cancer is a widespread disease that is defined as a malignant or invasive growth
Basic Radiation Therapy Terms
Basic Radiation Therapy Terms accelerated radiation: radiation schedule in which the total dose is given over a shorter period of time. (Compare to hyperfractionated radiation.) adjuvant therapy (add-joo-vunt):
NIA RADIATION ONCOLOGY CODING STANDARD. Dosimetry Planning
NIA RADIATION ONCOLOGY CODING STANDARD Dosimetry Planning CPT Codes: 77295, 77300, 77301, 77306, 77307, 77321, 77316, 77317, 77318, 77331, 77399 Original Date: April, 2011 Last Reviewed Date: November,
Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
With the project we hope to bring enhanced treatment for better care of our patients who will no
HKSH Symposium to Explore New Frontiers in Cancer Management Experience Sharing by Local and Overseas Experts HKSH Hopes to Introduce Proton Therapy Soon (15 June 2014, Hong Kong) A panel of renowned experts
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
CER, EHRs and the Elekta Radiation Oncology Data Alliance
CER, EHRs and the Elekta Radiation Oncology Data Alliance Joel Goldwein, MD Vice President, Medical Affairs September 11, 2009 Agenda Elekta and Elekta Software Cancer, Radiation Oncology and CER Radiation
Corporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy for Tumors of the Central File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_for_tumors
Department of Radiation Oncology
Department of Radiation Oncology Welcome to Radiation Oncology at Emory Clinic Every member of Emory Clinic Department of Radiation Oncology strives to provide the highest quality of care for you as our
Prostate Cancer Treatment: What s Best for You?
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
Northern Illinois. proton therapy facility
Northern Illinois proton therapy facility February, 2007 Northern Illinois proton therapy facility 2 Projected 16-State Service Area The Need Scale Legend Potential service region Existing proton therapy
E UROPEAN C URRICULUM V ITAE F ORMAT
E UROPEAN C URRICULUM V ITAE F ORMAT PERSONAL INFORMATION Name LOZZA LAURA Telephone 39-02-23902480 Fax 39-02-23902472 E-mail laura.lozza@istitutotumori.mi.it Nationality Italian Date of Birth 23.01.1960
Optimizing Adoption of Advanced Technology to Achieve High Value Cancer Care: The Case of Proton Therapy ECRI NCI Conference November 17, 2015
Optimizing Adoption of Advanced Technology to Achieve High Value Cancer Care: The Case of Proton Therapy ECRI NCI Conference November 17, 2015 Justin E. Bekelman, MD Associate Professor, Radiation Oncology
FEATURE ARTICLE. One precise dose
FEATURE ARTICLE Medical Physics Team at UNM Cancer Center Expands Treatment Choices From stereotactic radiosurgery to hippocampal-sparing treatment, the medical physics team provides new radiation therapy
Intensity-Modulated Radiation Therapy (IMRT)
Scan for mobile link. Intensity-Modulated Radiation Therapy (IMRT) Intensity-modulated radiotherapy (IMRT) uses linear accelerators to safely and painlessly deliver precise radiation doses to a tumor while
Web-based Dosimetry Training Program Arthur L. Boyer, Ph.D.
Web-based Dosimetry Training Program Arthur L. Boyer, Ph.D. The critical shortage of medical dosimetrists will require innovative methods to educate new personnel rapidly and adequately use limited resources.
The best for life. To nejlepší pro život. Advanced Cancer Treatment
The best for life. To nejlepší pro život. Advanced Cancer Treatment Proton therapy is a highly advanced and effective treatment of malignant tumors. Proton therapy offers a low risk of complications during
MEMORANDUM. Members of the State Hospital Review and Planning Council. Acting Director, Division of Health Facility Planning
MEMORANDUM TO: FROM: Members of the State Hospital Review and Planning Council Thomas Jung Acting Director, Division of Health Facility Planning DATE: March 11, 2010 RE: Proton Beam Therapy I. INTRODUCTION
intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis 11/2009 5/2016 5/2017 5/2016
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis
Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment.
Dictionary Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment. Applicator A device used to hold a radioactive source
CONQUERING CANCER SAVING LIVES. Mayo Clinic Proton Beam Therapy Program
CONQUERING CANCER SAVING LIVES Mayo Clinic Proton Beam Therapy Program A MALIGNANT TUMOR IS A TYRANT Cancer takes all the body s resources for itself invading and displacing surrounding tissues. Abolishing
Proton Therapy for Prostate Cancer
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Director, Proton Therapy Center Associate Professor Department of Radiation Oncology M.D. Anderson Cancer Center Randomized studies showing benefit
WellPoint Cancer Care Quality Program Provider FAQs
WellPoint Cancer Care Quality Program Provider FAQs WellPoint Cancer Care Quality Program What is the WellPoint Cancer Care Quality Program? Anthem Blue Cross and Blue Shield (Anthem) is pleased to bring
The Canadian National System for Incident Reporting in Radiation Treatment (NSIR-RT) Taxonomy March 2, 2015 V2
The Canadian National System for Incident Reporting in Radiation Treatment (NSIR-RT) Taxonomy March 2, 2015 V2 Taxonomy Data Category Number Description Data Fields and Menu Choices 1. Impact 1.1 Incident
Volumetric modulated arc therapy (VMAT) for prostate cancer
Planning study Volumetric modulated arc therapy (VMAT) for prostate cancer Institution: Purpose: Swedish Cancer Institute, Seattle, WA, USA In a community cancer center, treating prostate cancer comprises
Lung Cancer in 2015: A Multidisciplinary Update
Lung Cancer in 2015: A Multidisciplinary Update Invited Guest Faculty: Toronto General Hospital Toronto, Canada Saturday April 18, 2015 7:00 am-4:30 pm Westin Pasadena 191 N. Los Robles Avenue Pasadena,
Complex 2015 Changes to Radiation Oncology Coding
Complex 2015 Changes to Radiation Oncology Coding The Centers for Medicare & Medicaid Services (CMS) issued its Final Rule on October 31 outlining the codes it would recognize in calendar year (CY) 2015.
Proton Radiotherapy. Cynthia Keppel Scientific and Technical Director Hampton University Proton Therapy Institute. Lead Virginia.
Proton Radiotherapy Cynthia Keppel Scientific and Technical Director Hampton University Proton Therapy Institute Lead Virginia g October 16, 2009 About Proton Therapy Cancer is the (2nd) largest cause
Radiation Fibrosis Fact Sheet
Radiation Fibrosis Fact Sheet What is Radiation Fibrosis Syndrome (RFS), and when can it occur? Radiation Fibrosis Syndrome (RFS) is a term used to describe the multiple clinical symptoms associated with
UC DAVIS CANCER CENTER
UC DAVIS CANCER CENTER Endoscopic Enhancement by a Spectroscopic Cancer Detection System Ralph W. devere White, M.D. Professor and Chairman, Department of Urology Director, UC Davis Cancer Center University
METASTASES TO THE BONE
RADIATION THERAPY FOR METASTASES TO THE BONE Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY WHAT ARE BONE METASTASES? Cancer that starts
Professional Doctorate in Medical Physics (PDMP) Charles W. Coffey, II, PhD Radiation Oncology Department Vanderbilt University Medical Center Nashville, TN PDMP in Medical Physics PDMP What Is It? Impact
GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision
RADIATION THERAPY FOR GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT GYNECOLOGIC CANCERS Gynecologic cancers
Analysis of Set-up Errors during CT-scan, Simulation, and Treatment Process in Breast Cancer Patients
대한방사선종양학회지 2005;23(3):169~175 Analysis of Set-up Errors during CT-scan, Simulation, and Treatment Process in Breast Cancer Patients Department of Radiation Oncology, College of Medicine, Ewha Womans University
What is the CyberKnife System?
CYBERKNIFE Robotic Radiosurgery System PATIENT BROChURE 1 What is the CyberKnife System? have stabilizing frames bolted to their head or limit their breathing during treatment to minimize movement of the
National Medical Policy
National Medical Policy Subject: Policy Number: Proton Beam Radiotherapy NMP141 Effective Date*: November 2007 Updated: October 2014 This National Medical Policy is subject to the terms in the IMPORTANT